Comparison of Different Invasive Hemodynamic Measurements as a Prediction Tool for Mortality after Transcatheter Aortic Valve Replacement in Men: A Retrospective Observational Study

Paravalvular aortic regurgitation is an important complication after transcatheter aortic valve replacement (TAVR). Moderate to severe paravalvular aortic regurgitation has been clearly associated with late mortality; however, this can be a challenging diagnosis [1‐3]. Various invasive hemodynamics tests have been developed to complement aortography and echocardiography in the assessment of this complication. In two cohorts of patients who received the CoreValve device (n = 146) or the CoreValve/Sapien device (n = 122), the incidence of moderate to severe paravalvular aortic regurgitation was ≥15% [4, 5]. The investigators calculated the difference between the aortic diastolic pressure and left ventricular end-diastolic pressure (LVEDP) in relation to the aortic systolic pressure (aortic regurgitation index). They found a stepwise decrease in the aortic regurgitation index as the severity of paravalvular aortic regurgitation worsened. Aortic regurgitation index <25 was associated with increased 1-year mortality. Other invasive tests, such as the diastolic delta and the heart rate adjusted diastolic delta, have reached similar conclusions about impaired hemodynamics and late mortality [6, 7].

With current generation devices, the incidence of significant paravalvular aortic regurgitation is quite low. In our own practice, we observed that in some patients the aortic regurgitation index can be low despite no evidence of significant paravalvular aortic regurgitation. Moreover, no study has compared these different hemodynamic tests within the same cohort of patients. Accordingly, a reappraisal of the utility of these tests in predicting late mortality and their comparison against each other is warranted.

This study was approved by the Institutional Review Board at the University of Florida. This article is based on previously conducted studies and does not involve any new studies of human or animal subjects performed by any of the authors. All procedures were performed at the Malcom Randall Veterans Hospital for symptomatic severe aortic stenosis or mixed aortic stenosis/aortic regurgitation. Patients with either native or bioprosthetic aortic valve disease were included. Patients were evaluated in a multidisciplinary fashion by a Cardiologist and a Cardiothoracic Surgeon and considered appropriate for TAVR if they were deemed at least intermediate-risk (or high-risk/inoperable earlier in the program) for open-heart surgery. All patients had the following preoperative tests performed: transthoracic echocardiography, cardiac catheterization ± valve study, and TAVR-protocol computed tomography. Select intra-operative testing included transesophageal echocardiography, aortography, and valve study. The valve study was performed with a dual lumen pigtail catheter with simultaneous left ventricular and aortic pressures recorded before and approximately 5–10 min after valve implant. Postoperative transthoracic echocardiography was obtained on all patients.

Aortic regurgitation index was defined as 100 × [(aortic diastolic blood pressure—LVEDP)/systolic blood pressure] [4]. Diastolic delta was defined as the aortic diastolic blood pressure minus LVEDP [6]. Heart rate adjusted diastolic delta was defined as 80 × [(aortic diastolic blood pressure—LVEDP)/heart rate] [7]. Pulse pressure was defined as aortic systolic blood pressure minus aortic diastolic blood pressure [8]. Echocardiographic quantification of aortic regurgitation after TAVR was performed according to the Valve Academic Research Consortium (VARC-2) definitions [9], and Sellers classification was used to grade aortic regurgitation on aortic root angiogram semi-quantitatively by visual assessment [10].

Patients were classified into stages of aortic stenosis as per American College of Cardiology/American Heart Association valvular guidelines [11]. Stage D1 was defined as high-gradient aortic stenosis (mean aortic gradient ≥40 mm Hg). Stage D2 was defined as low-gradient low-ejection fraction aortic stenosis [mean aortic gradient <40 mm Hg and left ventricular ejection fraction (LVEF) <50%]. Stage D3 was defined as low-gradient normal-ejection fraction aortic stenosis (mean aortic gradient <40 mm Hg and LVEF ≥ 50%). The mean aortic gradient was preferentially obtained from the intraoperative valve study. If this was not performed, the preoperative valve study was recorded instead. If neither invasive study was performed, the preoperative transthoracic echocardiography derived value was obtained. The stroke volume index (SVi) was preferentially obtained from the preoperative invasive valve study. Thermodilution derived cardiac output was preferentially obtained; however, fick derived cardiac output was used if that was the only technique performed during right heart catheterization. If a preoperative valve study was not performed, the pre-operative transthoracic echocardiography derived SVi value was obtained instead.

Between September 2013 and November 2016, 155 transcatheter heart valve procedures were performed. Three of these were transcatheter mitral valve or mitral ring procedures and were excluded from further analysis. Another patient who had a Sapien XT implanted subsequently developed severe late paravalvular aortic regurgitation, presumably due to late recoil [12]. This was managed with a Sapien S3 valve-in-valve procedure approximately 1 year later. As this second procedure was not for treatment of aortic stenosis, it was excluded from further analysis.

The baseline characteristics of the study cohort (n = 151) are presented in Table 1. Stage D1 aortic stenosis was present in 52.3% of patients; mean gradient = 50.3 ± 10.7 mm Hg, LVEF = 53.7 ± 8.8%, and SVi = 37.1 ± 8.4 cc/m². Stage D2 aortic stenosis was present in 14.6% of patients; mean gradient = 28.8 ± 6.8 mm Hg, LVEF = 35.9 ± 8.8%, and SVi = 28.7 ± 6.3 cc/m². Stage D3 aortic stenosis was present in 33.1% of patients; mean gradient = 31.3 ± 5.8 mm Hg, LVEF = 56.0 ± 3.8%, and SVi = 37.8 ± 8.8 cc/m².

Procedural characteristics are presented in Table 2. Conscious sedation was used in 20%, and the most frequently implanted valve was the Sapien S3. Early outcomes are presented in Table 2. Early deaths were infrequent (30-day mortality = 2%). Only 2% of patients had moderate or greater paravalvular aortic regurgitation as assessed by postoperative transthoracic echocardiography.

Overall mortality was 15.2% at a mean follow-up of 12.7 ± 9.2 months. Aortic regurgitation index <25 versus ≥25, diastolic delta <19 mm Hg versus ≥19 mm Hg, and pulse pressure >60 mm Hg versus ≤60 mm Hg were not associated with total mortality. However, total mortality was 50% for heart rate adjusted diastolic delta <25 mm Hg/beats per minute versus 12.6% for heart rate adjusted diastolic delta ≥25 mm Hg/beats per minute (p = 0.017). In a multivariate Cox regression analysis, heart rate adjusted diastolic delta <25 mm Hg/beats per minute versus heart rate adjusted diastolic delta ≥25 mm Hg/beats per minute was associated with late mortality (HR 9.4, 95% CI 2.0–44, p = 0.004) (Table 3). Salient characteristics of the patients with heart rate adjusted diastolic delta <25 mm Hg/beats per minute are presented in Table 4.

Among a cohort of TAVR patients with low incidence of significant paravalvular aortic regurgitation, we observed that a low heart rate adjusted diastolic delta was independently associated with increased total mortality compared with a high heart rate adjusted diastolic delta. Aortic regurgitation index, diastolic delta, and pulse pressure were not associated with increased total mortality. Thirty day (2%) and 1-year mortality (15.2%) was low in this cohort of veterans from a single center experience.

As heart rate increases, diastole shortens resulting in higher aortic diastolic pressure and LVEDP. This may help to explain the superiority of the heart rate adjusted diastolic delta as an invasive hemodynamic test in capturing the complex interplay of heart rate and blood pressure. In the absence of significant aortic regurgitation, a low heart rate adjusted diastolic delta may reflect central aorta stiffness and/or an increase in LVEDP from diastolic dysfunction. Increased pulse pressure is a marker for central aorta stiffness. In an observational study of 22,576 patients with hypertension and coronary artery disease, increased pulse pressure was independently associated with increased all-cause mortality (nadir pulse pressure 60 mm Hg) [8]. The reference standard for non-invasively assessing central aorta stiffness is the aortic pulse wave velocity [13]. Increased pulse wave velocity has been independently associated with increased mortality among hypertensive patients with normal pulse pressure (mean pulse pressure 59 mm Hg) [14]. Pulse wave velocity may be an important risk factor among those without established atherosclerotic disease, while the pulse pressure becomes important later in the disease process [15]. Interestingly, TAVR may be superior to surgical aortic valve replacement in preserving aortic elasticity [16]. This could possibly be related to TAVR not resulting in mediastinal scar formation or inflammatory changes within the aorta [16]. At the present time, central aorta stiffness has not been viewed as an important prognostic factor among patients with valvular heart disease. How this condition is best diagnosed and treated are important future questions. For example, these patients may require different heart rate and/or blood pressure targets; however, these concepts would need to be prospectively evaluated.

Early procedural complications are captured with 30-day mortality, while the patient’s overall medical condition and frailty are better reflected in 1-year mortality [17, 18]. From the Society of Thoracic Surgeons/American College of Cardiology/Transcatheter Valve Therapies registry (STS/ACC/TVT), procedural success was documented at 92%, 30-day mortality, 4.6%–7.0%, and 1-year mortality, 21.6%–23.7% [19‐21]. Despite excellent acute procedural success and low early mortality, late mortality remains quite high nationally. Therefore, ongoing attempts to understand and improve long-term survival are important.

In addition to heart rate adjusted diastolic delta, other independent predictors of total mortality included severe pulmonary hypertension (mean ≥ 45 mm Hg), low SVi (<24 cc/m²), and moderate or greater paravalvular aortic regurgitation. The current incidence of significant paravalvular aortic regurgitation is quite low (<5%–6% incidence of moderate to severe paravalvular aortic regurgitation with the Sapien S3 and Evolut R devices) [21‐23]. In addition to device improvements, optimal valve implantation by avoiding implants within significant calcification in the left ventricular outflow tract may also be a contributing factor. As the incidence of significant paravalvular aortic regurgitation continues to decline, other patient characteristics will become more important in predicting late mortality. In fact, moderate to severe paravalvular aortic regurgitation was marginally significant in this dataset, which is likely a reflection of limited events for this outcome.

Previous studies have documented low echocardiography-derived SVi (<35 cc/m²) as a significant independent predictor of late mortality [24, 25]. By using receiver operator curve analysis, we determined that <24 cc/m² provided the best prediction of late mortality. This variable carried the strongest hazard ratio for late mortality among our four retained variables. Low flow predominately affects stage D2 aortic stenosis patients. In such patients, careful determination of the stroke volume through cardiac catheterization may be preferential to echocardiography derived valves. In patients with markedly reduced stroke volume, consideration could be given to optimization of flow before proceeding with TAVR. Examples could include multi-vessel coronary revascularization, restoration of sinus rhythm, cardiac resynchronization therapy, and control of systemic and/or pulmonary hypertension. We preferentially obtained the SVi from the pre-operative valve study, which may help to explain the different cut point from previous studies. Resting pulmonary hypertension has been reported in up to one third of patients with symptomatic aortic stenosis; however, this is usually mild in severity (23% with mild, 8.9% with moderate, and 4.8% with severe pulmonary hypertension) [26]. Severe pulmonary hypertension has been associated with late mortality after TAVR [27, 28]. However, some data suggest a gender effect that places women at disproportionate risk from pulmonary hypertension [29]. Our analysis, in 98% men, suggests that severe pulmonary hypertension may be equally hazardous in men.

Among a cohort of veterans with low incidence of paravalvular aortic regurgitation, we documented four variables that predicted late mortality: heart rate adjusted diastolic delta <25 mm Hg/beats per minute, SVi < 24 cc/m², mean pulmonary pressure ≥45 mm Hg, and moderate to severe paravalvular aortic regurgitation. Further research into the importance of central circulation physiology is warranted.